Literature DB >> 18983467

Can morphology predict 1p/19q loss in oligodendroglial tumours?

D Scheie1, M Cvancarova, S Mørk, K Skullerud, P A Andresen, I Benestad, E Helseth, T Meling, K Beiske.   

Abstract

AIMS: To investigate the relationship between phenotype and genotype in oligodendroglial tumours and evaluate whether 1p/19q status can be reliably predicted from histological findings. METHODS AND
RESULTS: Three neuropathologists reviewed the association between 10 histological variables, location and genetic losses at 1p, 19q and 17p13 in 63 oligodendroglial tumours (cohort 1). Based on these findings, a multiple logistic regression model for prediction of 1p/19q status was constructed. The ability of this model to predict 1p/19q status was tested on cohort 2, comprising 20 oligodendroglial tumours. Loss of heterozygosity at 1p, 19q and 17p13 was analysed using polymerase chain reaction. Combined 1p/19q loss and losses at 17p13 were mutually exclusive (P < 0.001). The variable H1a (more or <50% of cells with round, uniform nuclei and perinuclear halos) demonstrated the strongest association with 1p/19q status (odds ratio 11.9, 95% confidence interval 3.6, 39.6, P < 0.001). Calcifications, absence of gemistocytic cells and a non-temporal/non-insular location were also associated. The correct 1p/19q status was predicted in 80% of cases in cohort 2.
CONCLUSIONS: There is a strong association between phenotype and genotype in oligodendroglial tumours. However, even when all significant variables are accounted for, perfect prediction (100%) of 1p/19q status cannot be obtained.

Entities:  

Mesh:

Year:  2008        PMID: 18983467     DOI: 10.1111/j.1365-2559.2008.03160.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  8 in total

1.  A case for reclassifying infiltrating gliomas in adults.

Authors:  Nicholas F Marko; Robert J Weil
Journal:  J Neurooncol       Date:  2012-07-20       Impact factor: 4.130

2.  Prognostic variables in oligodendroglial tumors: a single-institution study of 95 cases.

Authors:  David Scheie; Torstein R Meling; Milada Cvancarova; Kari Skullerud; Sverre Mørk; Knut Lote; Tor J Eide; Eirik Helseth; Klaus Beiske
Journal:  Neuro Oncol       Date:  2011-08-19       Impact factor: 12.300

Review 3.  Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification.

Authors:  Adriana Olar; Erik P Sulman
Journal:  Semin Radiat Oncol       Date:  2015-02-23       Impact factor: 5.934

Review 4.  Molecular diagnostics of gliomas: state of the art.

Authors:  Markus J Riemenschneider; Judith W M Jeuken; Pieter Wesseling; Guido Reifenberger
Journal:  Acta Neuropathol       Date:  2010-08-17       Impact factor: 17.088

Review 5.  Progress on molecular biomarkers and classification of malignant gliomas.

Authors:  Chuanbao Zhang; Zhaoshi Bao; Wei Zhang; Tao Jiang
Journal:  Front Med       Date:  2013-05-17       Impact factor: 4.592

6.  Robust Cell Detection of Histopathological Brain Tumor Images Using Sparse Reconstruction and Adaptive Dictionary Selection.

Authors:  Hai Su; Fuyong Xing; Lin Yang
Journal:  IEEE Trans Med Imaging       Date:  2016-01-21       Impact factor: 10.048

Review 7.  Interrelationships between molecular subtype, anatomical location, and extent of resection in diffuse glioma: a systematic review and meta-analysis.

Authors:  Beverly I De Leeuw; Kirsten M Van Baarsen; Tom J Snijders; Pierre A J T Robe
Journal:  Neurooncol Adv       Date:  2019-10-01

8.  Biomarkers classification and therapeutic decision-making for malignant gliomas.

Authors:  Adriana Olar; Kenneth D Aldape
Journal:  Curr Treat Options Oncol       Date:  2012-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.